Patents by Inventor Robin Alec Fairhurst

Robin Alec Fairhurst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-alpha AND THEIR METHODS OF USE
    Publication number: 20220401422
    Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt form thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of disease.
    Type: Application
    Filed: April 27, 2021
    Publication date: December 22, 2022
    Inventors: Robin Alec FAIRHURST, Christine FRITSCH, Marc GERSPACHER, Jürgen Hans-Hermann HINRICHS, Jean-Baptiste Georges Armand LANGLOIS, Catherine LEBLANC, Tengfei LI, Edwige Liliane Jeanne LORTHIOIS, Christophe MURA, Cristina Montserrat NIETO-OBERHUBER, Milen TODOROV, Andrea VAUPEL, Nicolas WARIN, Rainer WILCKEN
  • Combinations of FGFR4 inhibitors and bile acid sequestrants
    Patent number: 11229643
    Abstract: The present invention relates to a pharmaceutical combination comprising an FGFR4 inhibitor and a bile acid sequestrant, to the use of the pharmaceutical combination in the treatment of cancer, to the use of a bile acid sequestrant to reduce or mitigate side-effects associated with FGFR4 inhibition therapy.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: January 25, 2022
    Assignee: NOVARTIS AG
    Inventors: Robin Alec Fairhurst, Diana Graus Porta, Jacqueline Kinyamu-Akunda, Andreas Joerg Mahl, Luigi Manenti, Andreas Weiss, Armin Wolf, Kuno Wuersch
  • Formylated N-heterocyclic derivatives as FGFR4 inhibitors
    Patent number: 10786492
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: September 29, 2020
    Assignee: NOVARTIS AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Thomas Knoepfel, Catherine Leblanc, Robert Mah
  • COMBINATIONS OF FGFR4 INHIBITORS AND BILE ACID SEQUESTRANTS
    Publication number: 20200261444
    Abstract: The present invention relates to a pharmaceutical combination comprising an FGFR4 inhibitor and a bile acid sequestrant, to the use of the pharmaceutical combination in the treatment of cancer, to the use of a bile acid sequestrant to reduce or mitigate side-effects associated with FGFR4 inhibition therapy.
    Type: Application
    Filed: November 1, 2017
    Publication date: August 20, 2020
    Applicant: NOVARTIS AG
    Inventors: Robin Alec FAIRHURST, Diana GRAUS PORTA, Jacqueline KINYAMU-AKUNDA, Andreas Joerg MAHL, Luigi MANENTI, Andreas WEISS, Armin WOLF, Kuno WUERSCH
  • OXAZOLIDIN-2-ONE-PYRIMIDINE DERIVATIVES AND THE USE THEREOF AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS
    Publication number: 20190382399
    Abstract: The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.
    Type: Application
    Filed: December 18, 2018
    Publication date: December 19, 2019
    Inventors: Robin Alec Fairhurst, Pascal Furet, Frank Stephen Kalthoff, Andreas Lerchner, Heinrich Rueeger
  • Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
    Patent number: 10507201
    Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: December 17, 2019
    Assignee: NOVARTIS AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Diana Graus Porta, Carolina Haefliger, Bo Han, Thomas Knöpfel, Catherine Leblanc, Lv Liao, Robert Mah, Masato Murakami, Pierre Nimsgern, Michael Palmer, Dale Porter, Sebastien Ripoche, Can Wang, Youzhen Wang, Andreas Weiss, Jing Xiong, Xianglin Zhao
  • USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS
    Publication number: 20190231760
    Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof
    Type: Application
    Filed: February 28, 2019
    Publication date: August 1, 2019
    Inventors: Nicole BUSCHMANN, Robin Alec FAIRHURST, Pascal FURET, Diana GRAUS PORTA, Carolina HAEFLIGER, Bo HAN, Thomas KNOPFEL, Catherine LEBLANC, Lv LIAO, Robert MAH, Masato MURAKAMI, Pierre NIMSGERN, Michael PALMER, Dale PORTER, Sebastien RIPOCHE, Can WANG, Youzhen WANG, Andreas WEISS, Jing XIONG, Xianglin ZHAO
  • Formylated N-heterocyclic derivatives as FGFR4 inhibitors.
    Publication number: 20190105309
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: December 5, 2018
    Publication date: April 11, 2019
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Thomas Knoepfel, Catherine Leblanc, Robert Mah
  • Benzothiazolone compound
    Patent number: 10251868
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: April 9, 2019
    Assignee: NOVARTIS AG
    Inventors: Jun Cao, Bernhard Erb, Robin Alec Fairhurst, Arnaud Grandeury, Shinji Hatakeyama, Magdalena Koziczak-Holbro, Xinzhong Lai, Philipp Lustenberger, Bernd Ulrich Riebesehl, Nicola Tufilli, Thomas Ullrich, Xiang Wu, Jianguang Zhou
  • USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS
    Publication number: 20190076412
    Abstract: The present invention relates to therapeutic uses of compounds of formula (1) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 13, 2018
    Publication date: March 14, 2019
    Inventors: Nicole BUSCHMANN, Robin Alec FAIRHURST, Pascal FURET, Thomas KNÖPFEL, Catherine LEBLANC, Lv LIAO, Robert MAH, Pierre NIMSGERN, Sebastien RIPOCHE, Jing XIONG, Bo HAN, Can WANG, Xianglin ZHAO
  • Oxazolidin-2-one-pyrimidine derivatives and the use thereof as phosphatidylinositol-3-kinase inhibitors
    Patent number: 10202371
    Abstract: The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: February 12, 2019
    Assignee: Novartis AG
    Inventors: Robin Alec Fairhurst, Pascal Furet, Frank Stephen Kalthoff, Andreas Lerchner, Heinrich Rueeger
  • Formylated N-heterocyclic derivatives as FGFR4 inhibitors
    Patent number: 10189813
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: January 29, 2019
    Assignee: NOVARTIS AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Thomas Knoepfel, Catherine Leblanc, Robert Mah
  • Pharmaceutical combinations
    Patent number: 10130629
    Abstract: A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: November 20, 2018
    Assignee: Novartis AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Jorge Garcia Fortanet, Pascal Furet, Diana Graus Porta, Nafeeza Hafeez, Bo Han, Thomas Knoepfel, Matthew J. LaMarche, Catherine Leblanc, Lv Liao, Robert Mah, Dale Porter, Can Wang, Markus Wartmann, Jing Xiong, Xianglin Zhao
  • USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS
    Publication number: 20180185341
    Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof
    Type: Application
    Filed: October 2, 2015
    Publication date: July 5, 2018
    Inventors: Nicole BUSCHMANN, Robin Alec FAIRHURST, Pascal FURET, Diana GRAUS PORTA, Carolina HAEFLIGER, Bo HAN, Thomas KNÖPFEL, Catherine LEBLANC, Lv LIAO, Robert MAH, Masato MURAKAMI, Pierre NIMSGERN, Michael PALMER, Dale PORTER, Sebastien RIPOCHE, Can WANG, Youzhen WANG, Andreas WEISS, Jing XIONG, Xianglin ZHAO
  • BENZOTHIAZOLONE COMPOUND
    Publication number: 20180140582
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.
    Type: Application
    Filed: January 22, 2018
    Publication date: May 24, 2018
    Applicant: NOVARTIS AG
    Inventors: Jun CAO, Bernhard ERB, Robin Alec FAIRHURST, Arnaud GRANDEURY, Shinji HATAKEYAMA, Magdalena KOZICZAK-HOLBRO, Xinzhong LAI, Philipp LUSTENBERGER, Bernd Ulrich RIEBESEHL, Nicola TUFILLI, Thomas ULLRICH, Xiang WU, Jianguang ZHOU
  • Benzothiazolone compound
    Patent number: 9913828
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: March 13, 2018
    Assignee: NOVARTIS AG
    Inventors: Jun Cao, Bernhard Erb, Robin Alec Fairhurst, Arnaud Grandeury, Shinji Hatakeyama, Magdalena Koziczak-Holbro, Xinzhong Lai, Philipp Lustenberger, Bernd Ulrich Riebesehl, Nicola Tufilli, Thomas Ullrich, Xiang Wu, Jianguang Zhou
  • PHARMACEUTICAL COMBINATIONS
    Publication number: 20180064709
    Abstract: A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
    Type: Application
    Filed: March 23, 2016
    Publication date: March 8, 2018
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Jorge Garcia Fortanet, Pascal Furet, Diana Graus Porta, Nafeeza Hafeez, Bo Han, Thomas Knoepfel, Matthew J. LaMarche, Catherine Leblanc
  • Formylated N-heterocyclic derivatives as FGFR4 inhibitors
    Publication number: 20180065951
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: March 23, 2016
    Publication date: March 8, 2018
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Thomas Knoepfel, Catherine Leblanc, Robert Mah
  • Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
    Patent number: 9896449
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: February 20, 2018
    Assignee: Novartis AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Thomas Knöpfel, Catherine Leblanc, Lv Liao, Robert Mah, Pierre Nimsgern, Sebastien Ripoche, Jing Xiong, Bo Han, Can Wang, Xianglin Zhao
  • Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
    Patent number: 9802917
    Abstract: The present invention relates to particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, to a process of making said particles, to pharmaceutical compositions comprising said particles and to method of treating cancers using said pharmaceutical compositions.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: October 31, 2017
    Assignee: Novartis AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Bo Han, Thomas Knöpfel, Catherine Leblanc, Lv Liao, Robert Mah, Franck Mallet, Julie Martz, Can Wang, Jing Xiong, Xianglin Zhao